{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:45:01Z","timestamp":1792201501730,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27936-4","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:26:22Z","timestamp":1766147182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis"],"prefix":"10.1038","volume":"15","author":[{"given":"Tomoya","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Imano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Kounami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuhiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Hiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takushi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"27936_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. C.A Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"C.A Cancer J. Clin."},{"key":"27936_CR2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers15061777","volume":"15","author":"I Manzanedo","year":"2023","unstructured":"Manzanedo, I., Pereira, F., Perez-Viejo, E. & Serrano, A. Gastric cancer with peritoneal metastases: current status and prospects for treatment. Cancers (Basel). 15, 1777. https:\/\/doi.org\/10.3390\/cancers15061777 (2023).","journal-title":"Cancers (Basel)."},{"key":"27936_CR3","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1245\/s10434-022-12312-7","volume":"29","author":"M Martins","year":"2022","unstructured":"Martins, M., Santos-Sousa, H., Araujo, F., Nogueiro, J. & Sousa-Pinto, B. Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: a systematic review and meta-analysis. Ann. Surg. Oncol. 29, 7528\u20137537. https:\/\/doi.org\/10.1245\/s10434-022-12312-7 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"27936_CR4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","volume":"22","author":"RA Seshadri","year":"2016","unstructured":"Seshadri, R. A. & Glehen, O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J. Gastroenterol. 22, 1114\u20131130. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1114 (2016).","journal-title":"World J. Gastroenterol."},{"key":"27936_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s40792-024-02022-5","volume":"10","author":"H Kumagai","year":"2024","unstructured":"Kumagai, H. et al. Stage IV gastric cancer with microsatellite instability-high achieving long-term survival by gastrectomy after nivolumab as third-line therapy: A case report and literature review. Surg. Case. Rep. 10, 221. https:\/\/doi.org\/10.1186\/s40792-024-02022-5 (2024).","journal-title":"Surg. Case. Rep."},{"key":"27936_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390, 2461\u20132471. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5 (2017).","journal-title":"Lancet."},{"key":"27936_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398, 27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2 (2021).","journal-title":"Lancet."},{"key":"27936_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234\u2013247. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6 (2022).","journal-title":"Lancet Oncol."},{"key":"27936_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00595-013-0603-8","volume":"44","author":"M Imano","year":"2014","unstructured":"Imano, M. & Okuno, K. Treatment strategies for gastric cancer patients with peritoneal metastasis. Surg. Today. 44, 399\u2013404. https:\/\/doi.org\/10.1007\/s00595-013-0603-8 (2014).","journal-title":"Surg. Today."},{"key":"27936_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000333803","volume":"47","author":"M Imano","year":"2011","unstructured":"Imano, M. et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur. Surg. Res. 47, 254\u2013259. https:\/\/doi.org\/10.1159\/000333803 (2011).","journal-title":"Eur. Surg. Res."},{"key":"27936_CR11","first-page":"4071","volume":"32","author":"M Imano","year":"2012","unstructured":"Imano, M. et al. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res. 32, 4071\u20134075 (2012).","journal-title":"Anticancer Res."},{"key":"27936_CR12","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.21873\/anticanres.12944","volume":"38","author":"M Shinkai","year":"2018","unstructured":"Shinkai, M. et al. Intraperitoneal administration of paclitaxel followed by paclitaxel, cisplatin, and S-1 chemotherapy for cytology-positive gastric cancer: A feasibility study. Anticancer Res. 38, 5969\u20135974. https:\/\/doi.org\/10.21873\/anticanres.12944 (2018).","journal-title":"Anticancer Res."},{"issue":"975","key":"27936_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00423-021-02410-7","volume":"407","author":"M Shinkai","year":"2022","unstructured":"Shinkai, M. et al. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis. Langenbeck Arch. Surg. 407(975), 983. https:\/\/doi.org\/10.1007\/s00423-021-02410-7 (2022).","journal-title":"Langenbeck Arch. Surg."},{"key":"27936_CR14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","volume":"36","author":"H Ishigami","year":"2018","unstructured":"Ishigami, H. et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J. Clin. Oncol. 36, 1922\u20131929. https:\/\/doi.org\/10.1200\/JCO.2018.77.8613 (2018).","journal-title":"J. Clin. Oncol."},{"key":"27936_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/cyto.b.21126","volume":"86","author":"J Kitayama","year":"2014","unstructured":"Kitayama, J. et al. Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis. Cytometr. B Clin. Cytom. 86, 56\u201362. https:\/\/doi.org\/10.1002\/cyto.b.21126 (2014).","journal-title":"Cytometr. B Clin. Cytom."},{"key":"27936_CR16","doi-asserted-by":"publisher","first-page":"969468","DOI":"10.3389\/fimmu.2022.969468","volume":"13","author":"K Takahashi","year":"2022","unstructured":"Takahashi, K. et al. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer. Front. Immunol. 13, 969468. https:\/\/doi.org\/10.3389\/fimmu.2022.969468 (2022).","journal-title":"Front. Immunol."},{"key":"27936_CR17","unstructured":"Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma \u2013 In 15th ed.,. 24-25 (Kanehara & Co., Ltd., Tokyo, 2017). (in Japanese)"},{"key":"27936_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P. & Sugarbaker, P. H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 82, 359\u2013374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23 (1996).","journal-title":"Cancer Treat. Res."},{"key":"27936_CR19","unstructured":"Agilent technologies Inc. PD-L1 IHC 28-8 pharmDx interpretation manual\u2013gastric adenocarcinoma, gastroesophageal junction (gej) adenocarcinoma, and esophageal adenocarcinoma."},{"key":"27936_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1007\/s11605-012-2059-3","volume":"16","author":"M Imano","year":"2012","unstructured":"Imano, M. et al. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J. Gastrointest. Surg. 16, 2190\u20132196. https:\/\/doi.org\/10.1007\/s11605-012-2059-3 (2012).","journal-title":"J. Gastrointest. Surg."},{"key":"27936_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10120-012-0182-1","volume":"16","author":"SH Hong","year":"2013","unstructured":"Hong, S. H. et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastr. Cancer. 16, 290\u2013300. https:\/\/doi.org\/10.1007\/s10120-012-0182-1 (2013).","journal-title":"Gastr. Cancer."},{"key":"27936_CR22","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","volume":"82","author":"EK Rowinsky","year":"1990","unstructured":"Rowinsky, E. K., Cazenave, L. A. & Donehower, R. C. Taxol: A novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82, 1247\u20131259. https:\/\/doi.org\/10.1093\/jnci\/82.15.1247 (1990).","journal-title":"J. Natl. Cancer Inst."},{"key":"27936_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2023.101884","author":"C Lim","year":"2023","unstructured":"Lim, C. et al. High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer. Nano Today https:\/\/doi.org\/10.1016\/j.nantod.2023.101884 (2023).","journal-title":"Nano Today"},{"key":"27936_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s12885-020-06964-5","volume":"20","author":"JIG Solari","year":"2020","unstructured":"Solari, J. I. G. et al. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells. B.M.C. Cancer 20, 474. https:\/\/doi.org\/10.1186\/s12885-020-06964-5 (2020).","journal-title":"B.M.C. Cancer"},{"key":"27936_CR25","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3390\/cancers13112821","volume":"13","author":"AP Hernandez","year":"2021","unstructured":"Hernandez, A. P. et al. Restoring the immunity in the tumor microenvironment: Insights into immunogenic cell death in Onco-therapies. Cancers (Basel). 13, 2821. https:\/\/doi.org\/10.3390\/cancers13112821 (2021).","journal-title":"Cancers (Basel)."},{"key":"27936_CR26","doi-asserted-by":"publisher","first-page":"17218","DOI":"10.1039\/d1nr05512g","volume":"13","author":"M Jiang","year":"2021","unstructured":"Jiang, M. et al. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. Nanoscale. 13, 17218\u201317235. https:\/\/doi.org\/10.1039\/d1nr05512g (2021).","journal-title":"Nanoscale."},{"key":"27936_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"27936_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imm.13178","volume":"160","author":"M Ono","year":"2020","unstructured":"Ono, M. Control of regulatory T-cell differentiation and function by T-cell receptor signalling and Foxp3 transcription factor complexes. Immunology. 160, 24\u201337. https:\/\/doi.org\/10.1111\/imm.13178 (2020).","journal-title":"Immunology."},{"issue":"1064","key":"27936_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00262-005-0092-8","volume":"55","author":"K Kono","year":"2006","unstructured":"Kono, K. et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55(1064), 1071. https:\/\/doi.org\/10.1007\/s00262-005-0092-8 (2006).","journal-title":"Cancer Immunol. Immunother."},{"key":"27936_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118. https:\/\/doi.org\/10.1038\/cr.2016.151 (2017).","journal-title":"Cell Res."},{"key":"27936_CR31","doi-asserted-by":"publisher","first-page":"1372837","DOI":"10.3389\/fimmu.2024.1372837","volume":"15","author":"OE Molina","year":"2024","unstructured":"Molina, O. E. et al. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes. Front. Immunol. 15, 1372837. https:\/\/doi.org\/10.3389\/fimmu.2024.1372837 (2024).","journal-title":"Front. Immunol."},{"key":"27936_CR32","doi-asserted-by":"publisher","first-page":"102629","DOI":"10.1016\/j.ctrv.2023.102629","volume":"120","author":"I Negura","year":"2023","unstructured":"Negura, I., Pavel-Tanasa, M. & Danciu, M. Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy. Cancer Treat. Rev. 120, 102629. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102629 (2023).","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"27936_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5230\/jgc.2025.25.e46","volume":"25","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. Distinct immunosuppressive tumor microenvironment in gastric cancer with peritoneal metastasis. J. Gastr. Cancer. 25(4), 605\u201320 (2025).","journal-title":"J. Gastr. Cancer."},{"key":"27936_CR34","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.3390\/cancers15245737","volume":"15","author":"EI Tognarelli","year":"2023","unstructured":"Tognarelli, E. I. et al. Natural killer T cell diversity and immunotherapy. Cancer. (Basel). 15, 5737. https:\/\/doi.org\/10.3390\/cancers15245737 (2023).","journal-title":"Cancer. (Basel)."},{"key":"27936_CR35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-014-1597-9","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu, L. et al. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma. Cancer Immunol. Immunother. 63, 1285\u20131296. https:\/\/doi.org\/10.1007\/s00262-014-1597-9 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"27936_CR36","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3390\/cancers13205174","volume":"13","author":"A Nelson","year":"2021","unstructured":"Nelson, A., Lukacs, J. D. & Johnston, B. The current landscape of NKT cell immunotherapy and the hills ahead. Cancers (Basel). 13, 5174. https:\/\/doi.org\/10.3390\/cancers13205174 (2021).","journal-title":"Cancers (Basel)."},{"key":"27936_CR37","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/eji.200939349","volume":"39","author":"L Lynch","year":"2009","unstructured":"Lynch, L. et al. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 39, 1893\u20131901. https:\/\/doi.org\/10.1002\/eji.200939349 (2009).","journal-title":"Eur. J. Immunol."},{"key":"27936_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","volume":"9","author":"D Krijgsman","year":"2018","unstructured":"Krijgsman, D., Hokland, M. & Kuppen, P. J. K. The role of natural killer T cells in cancer-A phenotypical and functional approach. Front. Immunol. 9, 367. https:\/\/doi.org\/10.3389\/fimmu.2018.00367 (2018).","journal-title":"Front. Immunol."},{"key":"27936_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.intimp.2004.09.013","volume":"5","author":"NZ Galante","year":"2005","unstructured":"Galante, N. Z. et al. Frequency of valpha24+Vbeta11+ NKT cells in peripheral blood of human kidney transplantation recipients. Int. Immunopharmacol. 5, 53\u201358. https:\/\/doi.org\/10.1016\/j.intimp.2004.09.013 (2005).","journal-title":"Int. Immunopharmacol."},{"key":"27936_CR40","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.4049\/jimmunol.167.6.3114","volume":"167","author":"LS Metelitsa","year":"2001","unstructured":"Metelitsa, L. S. et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167, 3114\u20133122. https:\/\/doi.org\/10.4049\/jimmunol.167.6.3114 (2001).","journal-title":"J. Immunol."},{"key":"27936_CR41","first-page":"129","volume":"12","author":"N Hafezi","year":"2015","unstructured":"Hafezi, N. et al. Increased expression of two alternative spliced variants of CD1d molecule in human gastric cancer. Iran. J. Immunol. 12, 129\u2013140 (2015).","journal-title":"Iran. J. Immunol."},{"key":"27936_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2478\/raon-2023-0046","volume":"57","author":"S Miceska","year":"2023","unstructured":"Miceska, S. et al. The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma. Radiol. Oncol. 57, 493\u2013506. https:\/\/doi.org\/10.2478\/raon-2023-0046 (2023).","journal-title":"Radiol. Oncol."},{"key":"27936_CR43","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 121, 3599\u20133608. https:\/\/doi.org\/10.1182\/blood-2012-04-425397 (2013).","journal-title":"Blood."},{"key":"27936_CR44","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3389\/fimmu.2019.01782","volume":"10","author":"S Nersesian","year":"2019","unstructured":"Nersesian, S., Glazebrook, H., Toulany, J., Grantham, S. & Boudreau, J. E. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front. Immunol. 10, 1782. https:\/\/doi.org\/10.3389\/fimmu.2019.01782 (2019).","journal-title":"Front. Immunol."},{"key":"27936_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oraloncology.2015.11.003","volume":"53","author":"X Zhou","year":"2016","unstructured":"Zhou, X., Su, Y. X., Lao, X. M., Liang, Y. J. & Liao, G. Q. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral Oncol. 53, 27\u201335. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.11.003 (2016).","journal-title":"Oral Oncol."},{"key":"27936_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12939","volume":"299","author":"D Michaud","year":"2021","unstructured":"Michaud, D., Steward, C. R., Mirlekar, B. & Pylayeva-Gupta, Y. Regulatory B cells in cancer. Immunol. Rev. 299, 74\u201392. https:\/\/doi.org\/10.1111\/imr.12939 (2021).","journal-title":"Immunol. Rev."},{"key":"27936_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.it.2012.10.007","volume":"34","author":"F Balkwill","year":"2013","unstructured":"Balkwill, F., Montfort, A. & Capasso, M. B. Regulatory cells in cancer. Trend. Immunol. 34, 169\u2013173. https:\/\/doi.org\/10.1016\/j.it.2012.10.007 (2013).","journal-title":"Trend. Immunol."},{"key":"27936_CR48","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","volume":"37","author":"X Wei","year":"2016","unstructured":"Wei, X. et al. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol. 37, 6581\u20136588. https:\/\/doi.org\/10.1007\/s13277-015-4538-0 (2016).","journal-title":"Tumour Biol."},{"key":"27936_CR49","doi-asserted-by":"publisher","unstructured":"Iglesia, M.D., Parker, J.S., Hoadley, K.A., Serody, J.S., Perou, C.M. & Vincent, B.G. Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl. Cancer Inst. 108 https:\/\/doi.org\/10.1093\/jnci\/djw144 (2016) https:\/\/www.uclad.com\/newsletters\/29111_pd-l1-ihc-28-8-interpretation-manual.pdf (2021).","DOI":"10.1093\/jnci\/djw144"},{"issue":"3","key":"27936_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4132\/jptm.2024.03.15","volume":"58","author":"S Ahn","year":"2024","unstructured":"Ahn, S. et al. Interpretation of PD-L1 expression in gastric cancer: Summary of a consensus meeting of Korean gastrointestinal pathologists. J. Pathol. Transl. Med. 58(3), 103\u201316 (2024).","journal-title":"J. Pathol. Transl. Med."},{"key":"27936_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.668612","volume":"8","author":"E Tejerina","year":"2021","unstructured":"Tejerina, E. et al. PD-L1 in cytological samples: A review and a practical approach. Front. Med. (Lausanne). 8, 668612 (2021).","journal-title":"Front. Med. (Lausanne)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27936-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:26:23Z","timestamp":1766147183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27936-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27936-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44193"}}